Observational data describes age-adjusted breast cancer death rates in US women for 2019
U.S. breast cancer death rates for women were described for 2019 in an observational report.
An observational study described age-adjusted death rates for female breast cancer in the US population for 2019. No specific intervention, …
In 2019, U.S. women had a specific age-adjusted death rate from breast cancer, according to a report that provided a snapshot without analyz…
Meta-analysis finds 32% higher breast cancer mortality hazard for Indigenous women despite lower incidence
Indigenous women face higher breast cancer mortality despite lower incidence rates
A systematic review and meta-analysis of 61 studies across seven countries found Indigenous women had lower breast cancer incidence but a 32…
Indigenous women have lower breast cancer rates but face a 32% higher risk of dying from the disease compared to non-Indigenous women.
Observational report examines breast cancer survival rates in US males
Study examines survival rates for men with breast cancer in the United States
An observational report examined breast cancer survival in males in the United States. The report did not provide specific survival rates, s…
A new report describes the survival rate of males diagnosed with breast cancer in the United States.
Letrozole reduces Ki67 in postmenopausal ER+/HER2- breast cancer after 7-30 days pre-surgery
Can a short course of letrozole before surgery help shrink hormone-sensitive breast cancer?
A phase 2 trial of 61 postmenopausal women with ER+/HER2- operable breast cancer evaluated a 7- to 30-day preoperative course of letrozole 2…
Doctors can now get a real-time snapshot of how hormone-sensitive breast cancer responds to letrozole before surgery in postmenopausal women…
Camizestrant 75 mg achieves maximal ER reduction in 5-7 days, well-tolerated in SERENA-3 WOO trial
Can a new breast cancer drug work in just days? Study shows it quickly reduces tumor fuel and slows growth.
In the presurgical SERENA-3 trial, camizestrant reduced ER expression by ~65% across all doses (75, 150, 300 mg) by 5-7 days in postmenopaus…
A new breast cancer drug cuts tumor fuel by 65% in just five to seven days and slows growth with minimal side effects at the lowest dose.
Sensorimotor rehab improves functional mobility, postural stability in breast cancer survivors
Could focusing on movement quality, not just strength, help breast cancer survivors move more easily?
In a multicenter RCT of 71 breast cancer survivors, an 8-week sensorimotor-based intervention (ReMAP) significantly improved functional mobi…
Breast cancer survivors who focused on movement control instead of just strength improved their ability to stand up and walk better after tr…
Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes
Can a Common Breast Cancer Drug Work Better for Some Patients?
This Phase 2/3 trial examines the relationship between ER and UGT SNPs and Raloxifene's efficacy and side effects in 600 BC-LCIS patients. R…
A study is testing if genetic markers can predict which breast cancer patients respond best to Raloxifene, potentially tailoring treatment f…